A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1

Wijdenes, John; Vooijs, Wim C.; Clément, Claude; Post, J.; Morard, Florence; Vita, Natalio; Laurent, Patrick; Sun, Ren-Xiao; Klein, Bernard; Dore, Jean-Michel

doi:10.1046/j.1365-2141.1996.d01-1811.x

Cited by 312 publications

(230 citation statements)

References 13 publications

Supporting

Mentioning

216

Contrasting

Unclassified

Order By: Relevance

“…In agreement with previous studies, all of the plasmablastic lymphoma cases in this study had a post-germinal center B-cell/plasma cell phenotype, expressing MUM1/IRF4 and CD138/syndecan-1, but negative for CD20. 3,[20][21][22] Furthermore, we observed that several markers that may be aberrantly expressed in plasma cell neoplasms, CD56, CD10 and CD4, were also expressed in most cases of plasmablastic lymphoma. CD56 and CD10, markers frequently expressed in plasma cell myeloma, [23][24][25] were positive in 5/9 and in 6/9 of the plasmablastic lymphoma cases in our series, respectively.…”

Section: Discussionmentioning

confidence: 80%

Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles

Vega

Chang

Medeiros³

et al. 2005

Modern Pathology

318

299

View full text Add to dashboard Cite

Plasmablastic lymphoma is an aggressive neoplasm that shares many cytomorphologic and immunophenotypic features with plasmablastic plasma cell myeloma. However, plasmablastic lymphoma is listed in the World Health Organization (WHO) classification as a variant of diffuse large B-cell lymphoma. To characterize the relationship between plasmablastic lymphoma and plasmablastic plasma cell myeloma, we performed immunohistochemistry using a large panel of B-cell and plasma cell markers on nine cases of plasmablastic lymphoma and seven cases of plasmablastic plasma cell myeloma with and without HIV/AIDS. The expression profiles of the tumor suppressor genes p53, p16, and p27, and the presence of Epstein-Barr virus (EBV) and human herpes virus type 8 (HHV-8) were also analyzed. All cases of plasmablastic lymphoma and plasmablastic plasma cell myeloma were positive for MUM1/IRF4, CD138, and CD38, and negative for CD20, corresponding to a plasma cell immunophenotype. PAX-5 and BCL-6 were weakly positive in 2/9 and 1/5 plasmablastic lymphomas, and negative in all plasmablastic plasma cell myelomas. Three markers that are often aberrantly expressed in cases of plasma cell myelomas, CD56, CD4 and CD10, were positive in 5/9, 2/5, and 6/9 plasmablastic lymphomas, and in 3/7, 1/5, and 2/7 plasmablastic plasma cell myelomas. A high Ki-67 proliferation index, overexpression of p53, and loss of expression of p16 and p27 were present in both tumors. No evidence of HHV-8 infection was detected in either neoplasm. The only significant difference between plasmablastic lymphoma and plasma cell myeloma was the presence of EBV-encoded RNA, which was positive in all plasmablastic lymphoma cases tested and negative in all plasma cell myelomas. In conclusion, most cases of AIDS-related plasmablastic lymphoma have an immunophenotype and tumor suppressor gene expression profile virtually identical to plasmablastic plasma cell myeloma, and unlike diffuse large B-cell lymphoma. These results do not support the suggestion in the WHO classification that plasmablastic lymphoma is a variant of diffuse large B-cell lymphoma.

show abstract

Section: Discussionmentioning

confidence: 80%

Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles

Vega

Chang

Medeiros³

et al. 2005

Modern Pathology

318

299

View full text Add to dashboard Cite

show abstract

“…CD138, also known as Syndecan-1, is expressed on plasma cells, but not on circulating B cells, T cells or monocytes. 25 The purity of plasma cells obtained by this method was more than 90%, as confirmed by flow cytometry (FAC sort: Becton Dickinson, San José, CA, USA) using the Paint a Gate program. Plasma cell leukaemia was not purified.…”

Section: Human Tissue Samplesmentioning

confidence: 84%

hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies

et al. 2006

View full text Add to dashboard Cite

Monoclonal gammopathies are a group of disorders characterized by clonal proliferation and accumulation of immunoglobulin-producing plasma cells. Multiple myeloma and monoclonal gammopathy of undetermined significance are the most common monoclonal gammopathies; the two comprise a spectrum of disorders, ranging from a relatively benign disease, monoclonal gammopathy of undetermined significance, to a malignant disease, multiple myeloma. Aberrant promoter methylation represents a primary mechanism of gene silencing during tumorigenesis. DNA repair systems act to maintain genome integrity in the presence of replication errors, environmental insults, and the cumulative effects of aging. The methylation patterns of two genes implicated in DNA repair, O6 methylguanine DNA methyl-transferase (MGMT) and human mutL homologue1 (hMLH1) have been detected in various solid tumours. With the purpose of studying the gene silencing of MGMT and hMLH1 in plasma cell disorders, we investigated the methylation status and expression of both genes in: 29 cases of multiple myeloma; one case of plasma cell leukaemia; 13 cases of monoclonal gammopathy of undetermined significance; and two cases of polyclonal plasmacytosis, using methylationspecific polymerase-chain reaction and immunohistochemical techniques. Methylation frequencies for MGMT were 23% in multiple myeloma and 8% in monoclonal gammopathy of undetermined significance. It was 10% for hMLH1 in multiple myeloma. None of the patients diagnosed with monoclonal gammopathy of undetermined significance had hMLH1 hypermethylated. In addition, 50% of myeloma cases had a loss of hMLH1 expression, whereas silencing of MGMT was observed in 43% of myeloma and 36% of samples with monoclonal gammopathy of undetermined significance. This study indicates that repair pathway defects play a role in the pathogenesis and evolution of monoclonal gammopathies, and suggests that inactivation of hMLH1 could be implicated in multiple myeloma tumorigenesis.

show abstract

“…Syndecan-1 immunohistochemistry is specific for plasma cells. It is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens (5,6). It has also been noted to stain plasma cells in routine paraffinembedded skin biopsy sections (Bayer-Garner and Smoller, unpublished observation).…”

Section: Discussionmentioning

confidence: 96%

“…The endogenous peroxidase activity was quenched with 0.3% peroxidase and nonspecific binding was quenched with horse serum block (Oncogene Research Products, Cambridge, MA). The DAKO Large Volume LSAB2 Alkaline Phosphatase Kit (DAKO) was used with 1:100 dilution of B-B4 (Serotec, Raleigh, NC), a mouse anti-human antibody that recognizes an epitope of human syndecan-1 (CD138) (5). Sections were incubated with biotinylated secondary antibody for thirty minutes, and then with streptavidin alkaline phosphatase for thirty minutes.…”

Section: Methodsmentioning

confidence: 99%

Plasma Cells in Chronic Endometritis are Easily Identified When Stained with Syndecan-1

2001

View full text Add to dashboard Cite

A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1

Cited by 312 publications

References 13 publications

Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles

Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles

hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies

Plasma Cells in Chronic Endometritis are Easily Identified When Stained with Syndecan-1

Contact Info

Product

Resources

About